Swedish Orphan Biovitrum establishes a MTN programme and issues bonds of SEK 3 billion

Swedish Orphan Biovitrum AB (publ) (“Sobi”) has established an MTN programme with a framework of SEK 10 billion or the equivalent amount in euro and has in connection therewith prepared a base prospectus that has been approved and registered by the Swedish Financial Supervisory Authority.

Under the programme, Sobi has the possibility to issue medium term notes in the capital market in Swedish kronor or euro. In connection with the establishment of the MTN programme, Sobi has issued three series of bonds thereunder for a total amount of SEK 3 billion.

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. Sobi’s share is listed on Nasdaq Stockholm.

Mannheimer Swartling advised Sobi in connection with the establishment of the MTN programme and the subsequent bond issue.


This website uses cookies to perform certain functions and help you navigate the site efficiently. A cookie is a text file with a small amount of information that is stored on your device. We share some of the information we obtain through these cookies with third parties. We only use cookies that are necessary for the site to function correctly and they therefore cannot be turned off. For further information, see Information on the use of cookies.